29-04-2025
Iraqi scientist files US patent for novel therapy for autism
Baghdad ( – A significant advancement in autism research has been made worldwide with the formal registration of a US patent by Iraqi researcher Adel Al-Salihi for a novel experimental therapy to treat autism spectrum disorder.
In a statement to the Iraqi News Agency (INA), Al-Salihi said that years of continuous field and lab effort had led to this accomplishment, noting that the step represents a scientific and humanitarian breakthrough that gives autistic children and their families throughout the world fresh hope.
Using rare natural human immune components developed within a legally protected secret substance, the patented therapy is the first of its type, according to Al-Salihi.
The Iraqi scientist explained that children with immune-based types of autism have demonstrated encouraging success rates between 70 and 86 percent in early studies.
With hopes to start clinical research soon, Al-Salihi stated that experimental research on extremely sensitive animal models is now being conducted.
The study is being carried out in cooperation with global specialists in immunology, neurology, and nanophysics, all within a rigorous scientific and ethical framework.
According to him, this is a historic time as the world's scientific community turns its attention to Baghdad, the location of what may be the first successful therapy to break through the stigma associated with autism.
Al-Salihi, whose study combines biological and environmental insights to better understand, prevent, and treat autism, a disorder that affects millions of people worldwide, has achieved numerous important scientific milestones, including the patent.
